Literature DB >> 22806755

Attitudes towards prenatal testing and termination of pregnancy in British Pakistani parents and relatives of children with recessive conditions in the UK.

S Ahmed1, M Ahmed, S M Sharif, E Sheridan, G R Taylor.   

Abstract

OBJECTIVE: To compare British Pakistani parents' and their relatives' attitudes to prenatal testing (PND) and termination of pregnancy (TOP) for a range of conditions.
METHOD: A total of 222 British Pakistani participants: 117 parents of children with a child with a genetic condition (52 fathers and 65 mothers) and 103 of their relatives (51 males and 52 females) completed a structured questionnaire about their attitudes toward PND and TOP for 30 different conditions.
RESULTS: Parents were more accepting of PND (P < 0.001) and TOP (P < 0.001) than their relatives for most of the conditions. Male relatives were consistently least interested in PND and TOP, except for conditions at the serious end of the continuum, where over 90% would opt for PND for quadriplegia and anencephaly, and over 60% would opt for TOP for these conditions.
CONCLUSION: The lower level of interest in PND and TOP in relatives, particularly men, may be due to lack of information disseminated by parents about their child's recessive inheritance and its implications for relatives, resulting in poor understanding of genetic risk. These findings highlight the need for the provision of proactive genetic counselling to raise awareness of genetic risk and facilitate informed reproductive decision-making in at-risk relatives.
© 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22806755     DOI: 10.1002/pd.3940

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  9 in total

1.  UK Pakistani views on the adverse health risks associated with consanguineous marriages.

Authors:  Mubasshir Ajaz; Nasreen Ali; Gurch Randhawa
Journal:  J Community Genet       Date:  2015-02-06

2.  Experiences of parents with a child with Down syndrome in Pakistan and their views on termination of pregnancy.

Authors:  Shenaz Ahmed; Louise D Bryant; Mushtaq Ahmed; Hussain Jafri; Yasmin Raashid
Journal:  J Community Genet       Date:  2012-10-23

3.  Acceptability of prenatal testing and termination of pregnancy in Pakistan.

Authors:  H Jafri; J Hewison; E Sheridan; S Ahmed
Journal:  J Community Genet       Date:  2014-08-01

4.  Decisions Regarding Pregnancy Termination Due to β-Thalassemia Major: a Mixed-Methods Study in Sistan and Baluchestan, Iran.

Authors:  Zahra Moudi; Ebrahim Miri-Moghaddam
Journal:  J Genet Couns       Date:  2016-09-28       Impact factor: 2.537

5.  Understanding of and attitudes to genetic testing for inherited retinal disease: a patient perspective.

Authors:  T A Willis; B Potrata; M Ahmed; J Hewison; R Gale; L Downey; M McKibbin
Journal:  Br J Ophthalmol       Date:  2013-06-28       Impact factor: 4.638

6.  Finding people who will tell you their thoughts on genomics-recruitment strategies for social sciences research.

Authors:  A Middleton; E Bragin; M Parker
Journal:  J Community Genet       Date:  2014-02-18

Review 7.  Meckel-Gruber Syndrome: An Update on Diagnosis, Clinical Management, and Research Advances.

Authors:  Verity Hartill; Katarzyna Szymanska; Saghira Malik Sharif; Gabrielle Wheway; Colin A Johnson
Journal:  Front Pediatr       Date:  2017-11-20       Impact factor: 3.418

8.  Diagnosis of a severe congenital anomaly: A qualitative analysis of parental decision making and the implications for healthcare encounters.

Authors:  Robyn Lotto; Lucy K Smith; Natalie Armstrong
Journal:  Health Expect       Date:  2018-02-02       Impact factor: 3.377

9.  Social and cultural influences on genetic screening programme acceptability: A mixed-methods study of the views of adults, carriers, and family members living with thalassemia in the UK.

Authors:  Felicity K Boardman; Corinna Clark; Elsita Jungkurth; Philip J Young
Journal:  J Genet Couns       Date:  2020-03-01       Impact factor: 2.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.